A great way to help others and yourself!
Pentucket Medical, in our continuing efforts to improve and offer advanced treatments, is involved in several clinical trials and is currently enrolling participants.
NOTE: This is a list of currently active trials. For a list of completed trials / research, please visit our Completed Trials page.
Clinical trials are entirely voluntary and patients may withdraw at any time, for any reason. We are currently participating in the following studies (More info is avalable for most trials. Please click on the title to learn more.):
To find out whether you are eligibile to participate in one of these studies, please contact the Clinical Research Office at (978) 521-3288
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes.
AMGEN LDL STUDY
A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of additional ldl-chloesterol reduction on major cardiovascular events when used in combination with statin therapy in patients with clinically evident cardiovascular disease
A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
A Randomized, Double-blind, Placebo-controlled, Event-driven trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infraction Patients with Type 2 Diabetes or Metabolic Syndrome.
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor with Clopidogrel treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients with Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor in paD)
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)
Trials Closed to Enrollment
Currently in Follow up phase:
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events
The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Determine Whether, in Patient with Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality.
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study of Evaluation of Efficacy and Safety of DU-176b Versus Warfarin in Subjects with Atrial Fibrillation - Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
Study to Establish the Clinical Benefit/Safety of Vytorin (Esetimibe/Simvastatin Tablet) vs Simvastatin in Subjects with Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial-IMPROVE IT)
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to assess the efficacy and safety of Darbepoetin alfa treatment on Mortality and Morbidity in Heart Failure (HF) subjects with symptomatic left ventricular systolic dysfunction and anemia.
Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarcation or Ischaemic Stroke in Patients with Type 2 Diabetes.
Trial of Aldosterone Antagonist Therapy in Adults with Preserved Ejection Fraction Congestive Heart Failure (TOPCAT).